Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer

British Journal of Cancer

Volumn 75, Issue 12, 1997, Pages 1793-1801

  Ganesh, S ^a   Sier, C F M ^a   Heerding, M M ^a   Van Krieken, J H J M ^a   Griffioen, G ^a   Welvaart, K ^a   Van De Velde, C J H ^a   Verheijen, J H ^b   Lamers, C B H W ^a   Verspaget, H W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

Author keywords

Colorectal cancer; Plasminogen activator; Prognosis; Survival

Indexed keywords

PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; UROKINASE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; COLORECTAL CANCER; FEMALE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 8244225180     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.306     Document Type: Article

References (72)

1. Al-Sheneber IF, Shibata HR, Sampaiis J and Jothy S (1993) Prognostic significance of proliferating cell nuclear antigen expression in colorectal cancer. Cancer 71: 1954-1959
2. Astler VB and Coller FA (1954) The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 139: 846-852
3. Beahrs OH (1942) Staging of cancer of the colon and rectum. Cancer 70 (suppl. 5): 1393-1396
4. Beart RW (1990) Colon, rectum, and anus. Cancer 33: 684-688
5. Beart RW, van Heerden JA and Beahrs OH (1978) Evolution in the pathologic staging of carcinoma of the colon. Surg Gynecol Obstet 146: 257-259
6. Binnema DJ, van Iersel JJL and Dooijewaard G (1986) Quantitation of urokinase antigen in plasma and culture media by use of an ELISA. Thromb Res 43: 569-577
7. Bouchet C, Spyratos F, Martin PM, Hacène K, Gentile A and Oglobine J (1994) Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 69: 398-405
8. Cox DR (1972) Regression models and life-tables. J R Stat Soc (B) 34: 187-220
9. Crowley CW, Cohen RL, Lucas BK, Liu G, Shuman MA and Levinson AD (1993) Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 90: 5021-5025
10. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS and Skriver L (1985) Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44: 139-266
11. de Bruin PAF, Griffioen G, Verspaget HW, Verheijen JH and Lamers CBHW (1987) Plasminogen activators and tumor development in the human colon, activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas. Cancer Res 47: 4654-4657
12. de Bruin PAF, Crama-Bohouth G, Verspaget HW, Verheijen JH, Dooijewaard G, Weterman IT and Lamers CBHW (1988) Plaminogen activators in the intestine of patients with inflammatory bowel disease. Thromb Haemost 60: 262-266
13. de Vries TJ, Quax PHA, Denijn M, Verrijp KN, Verheijen JH, Verspagel HW, Weidle UH, Ruiter DJ and van Muijen GNP (1994) Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 144: 70-81
14. Duffy MJ (1993) Urokinase-type plasminogen activator and malignancy. Fibrinolysis 7: 295-302
15. Duffy MJ, Reilly D, Nolan N, O'Higgins N, Fennelly JJ and Andreasen P (1992) Urokinase plasminogen activator, a strong and independent prognostic marker in breast cancer. Fibrinolysis 6 (suppl. 4): 55-57
16. Dukes CE (1932) The classification of cancer of the rectum. J Pathol 35: 323-332
17. Dukes CE and Bussey HJR (1958) The spread of cancer and its effect on prognosis. Br J Cancer 12: 309-320
18. Enblad P, Adami HO, Bergström R, Glimelius B, Krusemo UB and Pählman L (1988) Improved survival of patients with cancers of the colon and rectum? J Natl Cancer Inst 80: 586-591
19. Fisher B, Wolmark N, Rockette H, Redmond C, Deutsch M, Wickerham DL, Fisher ER, Caplan R, Jones J, Lerner H, Gordon P, Feldman M, Cruz A, Legault-Poisson S, Wexler M, Lawrence W and Robidoux A (1988) Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer, results from NSABP protocol R-01. J Natl Cancer Inst 80: 21-29
20. Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Bontenbal M, Jänicke F and Klijn JGM (1992) Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52: 6101-6105
21. Foekens JA, Buessecker F, Peters HA, Krainick U, van Putten WLJ, Look MP, Klijn JGM and Kramer MD (1995) Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 55: 1423-1427
22. Ganesh S, Sier CFM, Griffioen G, Vloedgraven HJM, de Boer A, Welvaart K, van de Velde CJH, van Krieken JHJM, Verheijen JH, Lamers CBHW and Verspaget HW (1994a) Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 54: 4065-4071
23. Ganesh S, Sier CFM, Heerding MM, Griffioen G, Lamers CBHW and Verspaget HW (1994b) Urokinase receptor and colorectal cancer survival. Lancet 344: 401-402
24. Ganesh S, Sier CFM, Heerding MM, van Krieken JHJM, Griffioen G, Welvaart K, van de Velde CJH, Verheijen JH, Lamers CBHW and Verspaget HW (1996) Prognostic value of the plasminogen activation system in patients with gastric carcinoma. Cancer 77: 1035-1043
25. Greenwald P (1992) Colon cancer overview. Cancer 70 (suppl 5): 1206-1215
26. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K and Blichert-Toft M (1993) High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521
27. Hart DA (1992) Dysregulation of plasminogen activators in cancer - potential role in invasion, metastasis and as a prognostic indicator. Fibrinolysis 6 (suppl 1): 11-15
28. Hasui Y, Marutsuka K, Suzumiya J, Kitada S, Osada Y and Sumiyoshi A (1992) The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int J Cancer 50: 871-873
29. Heiss MM, Babic R, Allgayer H, Gruetzner KU, Jauch KW, Loehrs U and Schildberg FW (1995) Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol 13: 2084-2093
30. Hesketh PJ and Bulger KN (1991) Role of adjuvant therapy in colorectal cancer. Adv Intern Med 36: 219-247
31. Hind R, Johnson CD and Rew DR (1992) Surgical excision alone is adequate treatment for primary colorectal cancer. Ann R Coll Surg 74: 63-67
32. Jänicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, Gössner W, Graeff H (1990) Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4: 69-78
33. Jänicke F, Schmitt M and Graeff H (1991) Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost 17: 303-312
34. Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
35. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, Kubista TP, Poon MA, Meyers WC, Mailliard JA, Twito DI, Morton RF, Veeder MH, Witzig TE, Cha S and Vidyarthi SC (1991) Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 324: 709-715
36. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193: 265-275
37. Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH and Mailliard JA (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322: 352-358
38. Mulcahy HE, Duffy MJ, Gibbons D, McCarthy P, Parfrey NA, O'Donoghue DP and Sheahan K (1994) Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 344: 583-584
39. Nacopoulou L, Azaris P, Papacharalampous N and Davaris P (1981) Prognostic significance of histologic host response in cancer of the large bowel. Cancer 47: 930-936
40. Nakamura M, Konno H, Tanaka T, Maruo Y, Nishino N, Aoki K, Baba S, Sakaguchi S, Takada Y and Takada A (1992) Possible role of plasminogen activator inhibitor 2 in the prevention of the metastasis of gastric cancer tissues. Thromb Res 65: 709-719
41. Nekarda H, Schmitt M, Ulm K, Wenninger A, Vogelsang H, Becker K, Roder JD, Fink U and Siewert JR (1994) Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 54: 2900-2907
42. Nishino N, Aoki K, Tokura Y, Sakaguchi S, Takada Y and Takada A (1988) The urokinase type of plasminogen activator in cancer of digestive tracts. Thromb Res 50: 527-535
43. O'Connell MJ, Schaid DJ, Ganju V, Cunningham J, Kovach JS and Thibodeau SN (1992) Current status of adjuvant chemotherapy for colorectal cancer. Cancer 70: 1732-1739
44. Öhman U (1985) Coloreclal carcinoma. A survey of 1345 cases 1950-1984. Acta Chir Scand 151: 675-679
45. Ossowski L, Russo-Payne H and Wilson EL (1991) Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res 51: 274-281
46. Patt YZ (1993) Regional hepatic arterial chemotherapy for colorectal cancer metastatic to the liver, the controversy continues. J Clin Oncol 11: 815-819
47. Pedersen H, Brünner N, Francis D, Østerlind K, Rønne E, Hansen HH, Danø K and Grøndahl-Hansen J (1994) Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 54: 4671-4675
48. Ponz de Leon M, Sant M, Micheli A, Sacchetti C, Di Gregorio C, Fante R, Zanghieri G, Melotti G and Gatta G (1992) Clinical and pathologic prognostic indicators in colorectal cancer. Cancer 69: 626-635
49. Pretlow TP, Keith EF, Cryar AK, Bartolucci AA, Pitts AM, Pretlow II TG, Kimball PM and Boohaker EA (1983) Eosinophil infiltration of human colonic carcinomas as a prognostic indicator. Cancer Res 43: 2997-3000
50. Quax PHA, van Muijen GNP, Weening-Verhoeff EJD, Lund LR, Danø K, Ruiter DJ and Verheijen JH (1991) Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation. J Cell Biol 115: 191-199
51. Rijken DC, van Hinsbergh VWM and Sens EHC (1984) Quantitation of tissue-type plasminogen activator in human endothelial cell cultures by use of an enzyme immunoassay. Thromb Res 33: 145-153
52. Saksela O (1985) Plasminogen activation and regulation of pericellular proteolysis. Biochim Biophys Acta 823: 35-65
53. Sandforth F, Witzel L, Balzer T, Gutschmidt S, Janicke I and Riecken EO (1991) Identification of patients at high risk for colorectal carcinoma from biopsy studies of the apparently normal colorectal mucosa. A multivariate analysis. Eur J Clin Invest 21: 295-302
54. Sato T, Nishimura G, Yonemura Y, Nojima N, Ninomiya I, Fujimura JT, Sugiyama K, Miwa K, Miyazaki I, Nonomura A and Yamaguchi Y (1995) Association of immunohistochemical detection of urokinase-type plasminogen activator with metastasis and prognosis in colorectal cancer. Oncology 52: 347-352
55. Schultz RM, Yu H and Zhang JY (1992) The role of urokinase and urokinase inhibitor in tumour cell metastasis. Fibrinolysis 6 (suppl 1): 23-29
56. Schwartz BS and Bradshaw JD (1992) Regulation of plasminogen activator inhibitor mRNA levels in lipopolysaccharide-stimulated human monocytes. J Biol Chem 267: 7089-7094
57. Sheehan AL and Shepherd NA (1991) Practicalities in the pathological staging of colorectal cancer. Cancer Topics 8: 58-59
58. Sier CFM, Verspaget HW, Griffioen G, Verheijen JH, Quax PHA, Dooijewaard G, de Bruin PAF and Lamers CBHW (1991) Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implication of urokinase in colorectal carcinogenesis. Gastroenterology 101: 1522-1528
59. Sier CFM and Quax PHA, Vloedgraven HJM, Verheijen JH, Griffioen G, Ganesh S, Lamers CBHW, Verspaget HW (1993a) Increased urokinase receptor levels in human gastrointestinal neoplasia and related liver metastases. Invasion Metastasis 13: 277-288
60. Sier CFM, Verspaget HW, Griffioen G, Ganesh S, Vloedgraven HJM and Lamers CBHW (1993b) Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach. Gut 34: 80-85
61. Sier CFM, Vloedgraven HJM, Ganesh S, Griffioen G, Quax PHA, Verheijen JH, Dooijewaard G, Welvaart K, van de Velde CJH, Lamers CBHW and Verspaget HW (1994) Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology 107: 1449-1456
62. Sinnige HAM and Mulder NH (1991) Colorectal carcinoma: an update. Neth J Med 38: 217-228
63. Sumiyoshi K, Baba S, Sakaguchi S, Urano T, Takada Y and Takada A (1991) Increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer, possible roles in tumor progression and metastasis. Thromb Res 63: 59-71
64. Takai S, Yamamura M, Tanaka K, Kawanishi H, Tsuji M, Nakane Y, Hioki K and Yamamoto M (1991) Plasminogen activators in human gastric cancers: correlation with DNA ploidy and immunohistochemical staining. Int J Cancer 48: 20-27
65. Tanaka N, Fukao H, Ueshima S, Okada K, Yasutomi M and Matsuo O (1991) Plasminogen activator inhibitor 1 in human carcinoma tissues. Int J Cancer 48: 481-484
66. Vassalli JD, Sappino AP and Belin D (1991) The plasminogen activator/plasmin system. J Clin Invest 88: 1067-1072
67. Verheijen JH, Mullaart E, Chang GTG, Kluft C and Wijngaards G (1982) A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemostas 48: 266-269
68. Watt AG and House AK (1978) Colonic carcinoma, a quantitative assessment of lymphocytic infiltration at the periphery of colorectal tumors related to prognosis. Cancer 41: 279-282
69. Wiggers T, Arends JW and Volovics A (1988) Regression analysis of prognostic factors in colorectal cancer after curative resections. Dis Colon Rectum 31: 33-41
70. Williams ST and Bean RW (1992) Staging of colorectal cancer. Semin Surg Oncol 8: 89-93
71. Winawer SJ, Zauber AG, Stewart E and O'Brien MJ (1991) The natural history of colorectal cancer. Opportunities for intervention. Cancer 67: 1143-1149
72. Wolmark N, Fisher B, Rockette H, Redmond C, Wickerham DL, Fisher ER, Jones J, Glass A, Lerner H, Lawrence W, Prager D, Wexler M, Evans J, Cruz A, Dimitrov N and Jochimsen P (1988) Postoperative adjuvant chemotherapy or BCG for colon cancer, results from NSABP Protocol C-01. J Natl Cancer Inst 80: 30-36